Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

[1]  E. Oki,et al.  O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites , 2020 .

[2]  S. Kopetz,et al.  NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type. , 2020 .

[3]  A. Vivancos,et al.  Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples , 2019, Scientific Reports.

[4]  N. Pavlidis,et al.  The Developing Story of Predictive Biomarkers in Colorectal Cancer , 2019, Journal of personalized medicine.

[5]  G. Giannini,et al.  Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer , 2019, Cancers.

[6]  I. Zlobec,et al.  Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree? , 2018, Front. Med..

[7]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[8]  G. Pentheroudakis,et al.  Current and future biomarkers in colorectal cancer , 2017, Annals of gastroenterology.

[9]  O. Abdel-Wahab,et al.  Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia , 2016, Proceedings of the National Academy of Sciences.

[10]  M. Loh,et al.  Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia , 2016, Proceedings of the National Academy of Sciences.

[11]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[13]  N. Normanno,et al.  RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.